TARGET VALIDATION AND EXPERIMENTAL ACTIVITY OF FUNCTIONALLY SUBSTITUTED 1,3,4-THIADIAZOLES: A CRITICAL SECONDARY ANALYSIS

Authors

  • Basirova Guzel Rasulovna Andijan State Medical Institute image/svg+xml Author

Keywords:

1,3,4-thiadiazole; molecular docking; target validation; carrageenan-induced edema; alloxan-induced diabetes; critical appraisal.

Abstract

 Molecular docking and animal experiments have both been reported for functionally substituted 1,3,4-thiadiazoles, but interpretation requires careful alignment of computational targets with disease biology. Objective: To critically integrate previously published docking observations with in vivo anti-inflammatory and glucose-lowering findings while checking the identity of the deposited protein structures. Methods: A secondary narrative appraisal of three publications from 2024 was undertaken. Reported ligand identities, protein Data Bank codes, carrageenan-induced edema and alloxan-induced hyperglycemia outcomes were extracted without generating new docking scores or biological measurements. The target identifiers were checked against their Protein Data Bank records. Results: The original docking abstract identified diethyl 2,2′-((1,3,4-thiadiazole-2,5-diyl)bis(sulfanediyl))diacetate as a promising ligand, whereas an animal study highlighted the corresponding diacetohydrazide in assays of inflammation and glycemia. Critically, PDB 6W5C represents a Cas12i–RNA–DNA complex rather than a validated inflammatory target; PDB 2DSQ describes an insulin-like growth factor/IGF-binding protein complex, not a validated antidiabetic therapeutic target in the cited report. Conclusion: The animal results justify further investigation of selected thiadiazoles, but the docking claims cannot currently be taken as mechanistic confirmation. Re-docking against validated disease-relevant targets and independent experimental validation are needed.

References

1.Basirova, G. R. (2024). Молекулярный докинг производных 1,3,4 тиадиазола [Molecular docking of 1,3,4-thiadiazole derivatives]. Academic Research in Modern Science, 121–122. https://doi.org/10.5281/zenodo.13968337

2.Basirova, G. R., Zhaloliddinov, F. Yu., Makhmudov, L. U., & Babayev, B. N. (2024). Synthesis and pharmacological evaluation of new 1,3,4-thiadiazole derivatives. Science and Innovation, 3(11), 139–143. https://doi.org/10.5281/zenodo.14251419

3.Basirova, G. R., Makhmudov, L. U., Usmonov, Sh. T., Tagayalieva, N. A., & Babayev, B. N. (2024). Определение острой токсичности и воспалительной активности производных 1,3,4-тиадиазолов [Determination of acute toxicity and inflammatory activity of 1,3,4-thiadiazole derivatives]. Journal of IQRO, 13(1).

4.RCSB Protein Data Bank. Entry 6W5C: Cryo-EM structure of Cas12i(E894A)-crRNA-dsDNA complex. https://doi.org/10.2210/pdb6W5C/pdb

5.RCSB Protein Data Bank. Entry 2DSQ: Structural basis for the inhibition of insulin-like growth factors by IGF binding proteins. https://doi.org/10.2210/pdb2DSQ/pdb

6.OECD. (2002). Test No. 420: Acute Oral Toxicity—Fixed Dose Procedure. OECD Publishing. https://doi.org/10.1787/9789264070943-en

Downloads

Published

2026-11-05